One Model Named "Ethical AI Solution of the Year" in 2025 AI Breakthrough Awards
AUSTIN, Texas — One Model, the People Analytics platform trusted by enterprise HR teams, today announced that it has been named 'Ethical AI Solution of the Year' in the 8th annual AI Breakthrough Awards. The program, which received more than 5,000 nominations from 20+ countries, honors the top companies, products, and leaders in AI around the world.
Article content
Article content
'We've built our platform on the idea that AI should be transparent, usable, and grounded in reality,' said Chris Butler, CEO of One Model.
Built for Today's CHRO
Article content
CHROs are facing complex demands—shrinking budgets, increasing scrutiny, and the need to make sensitive workforce decisions with speed and precision. For them, ethical AI isn't a bonus. It's the baseline. Transparent, defensible data is the only way to earn trust with their teams, peers, and boards. That's exactly what One Model was built to deliver.
Article content
What Sets One Model Apart
Article content
One Model turns messy, siloed workforce data into structured insight that HR teams can actually use. It provides full transparency into every model, variable, and recommendation—so users can see how predictions are made, and why. No black boxes. No guesswork.
Article content
With One AI Recipes, HR teams can build predictive models step-by-step using intuitive templates. They can adjust for variables like tenure, performance, geography, or demographics—all without needing data science expertise. And with One AI Assistant, a generative tool, HR leaders can uncover trends, spot outliers, and get fast, tailored recommendations from their own data—without waiting on a dashboard or a data team.
Article content
A Commitment to Transparency
Article content
'We've built our platform on the idea that AI should be transparent, usable, and grounded in reality,' said Chris Butler, CEO of One Model. 'This award is a reflection of that philosophy—and of our belief that HR leaders deserve clear, defensible answers to the hardest people questions. That's what we're here to continue delivering.'
Article content
Industry Recognition
Article content
'One Model sets itself apart by addressing the challenges faced by HR professionals with its flexible, transparent, and accessible AI-powered people analytics platform. One of the biggest challenges in adopting AI for HR is fragmented workforce data across systems. Most AI solutions rely on generalized data and obscure models, resulting in insights that don't align with specific organizational needs,' said Steve Johansson, managing director at AI Breakthrough. 'Through data transparency, ethical AI, and customizable, user-friendly tools, One Model is revolutionizing people analytics. It empowers HR professionals to make informed decisions with confidence, driving real business outcomes.'
Article content
About the AI Breakthrough Awards
Article content
The AI Breakthrough Awards program highlights excellence across a broad set of categories, including Generative AI, NLP, AIOps, Agentic AI, Robotics, and industry-specific applications. Now in its eighth year, the awards shine a spotlight on the companies shaping the future of artificial intelligence.
Article content
About One Model
Article content
One Model helps organizations unlock the full value of their workforce data. The platform combines secure data orchestration, advanced analytics, machine learning, and narrative storytelling to drive smarter, faster decisions. To learn more, visit www.onemodel.co.
Article content
About AI Breakthrough
Article content
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com.
Article content
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
2 Dividend Stocks to Buy for Decades of Passive Income
Key Points Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits for a long time to come. That's thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon. These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVie AbbVie is a pharmaceutical leader with a large portfolio of approved products, none more important than a duo of immunology medicines: Skyrizi and Rinvoq. In the first quarter, the company's revenue increased by 8.4% year over year to $13.3 billion, while its adjusted earnings per share came in at $2.46, 6.5% higher than the year-ago period. These results are all the more impressive considering AbbVie faced a major patent cliff just two years ago; however, it has since recovered, largely thanks to Skyrizi and Rinvoq. The former generated $3.4 billion in sales during the period, representing a 70.5% year-over-year increase. Rinvoq's revenue came in at $1.7 billion, 57.2% higher than the year-ago period. Management predicts their combined annual sales will exceed $31 billion by 2027. Not only is that significantly higher than the $17.7 billion they racked up last year, it's also $4 billion higher than their previous guidance. Skyrizi and Rinvoq are expected to drive top-line growth well into the 2030s. Although they will eventually lose patent protection, they demonstrate AbbVie's ability to navigate even the biggest patent cliffs, a quality that is essential for any pharmaceutical company to thrive over the long term. AbbVie has other products that help drive revenue growth, and, equally important, it has a deep pipeline that it routinely strengthens through acquisitions. In March, the company announced a licensing deal with Denmark-based Gubra A/S for GUB014295, an investigational weight management therapy. AbbVie paid $350 million up front for this candidate, with potential milestones of $1.9 billion, not including royalties. AbbVie entered the fast-growing weight loss market with this move; GUB014295 might not pan out, but AbbVie's large pipeline, with approximately 90 products in development, should allow it to launch brand-new products frequently, navigate patent cliffs, and remain successful over the long run. Now turning to the company's dividend, AbbVie has increased its payouts by 310% since 2013. And counting the time it spent under Abbott Laboratories' name, AbbVie is a Dividend King with 53 consecutive years of payout increases. These facts, from AbbVie's underlying business to the company's dividend track record, point to a company capable of sustaining a passive income program for a long time. 2. Abbott Laboratories Abbott Laboratories is best known for its leadership in the medical device space, where it markets dozens of products across multiple therapeutic areas. The company also operates a diagnostic business and has a presence in the pharmaceutical and nutrition industries. Abbott Laboratories' operations are diversified, which can help it overcome challenges in specific segments. That's one of the company's strengths. Here's another: Abbott Laboratories has been a leader in the highly regulated healthcare sector for decades. The company has built a solid reputation with physicians and consumers, all of whom are more likely to gravitate toward the brands they know and trust. In the medical device field, Abbott is a trusted brand. And thanks to its vast portfolio, it generates consistent revenue and earnings. Abbott's biggest growth driver in recent years has been its diabetes care segment, led by its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. As the company noted, the FreeStyle Libre has become the most successful medical device in history in terms of dollar sales. That's no small feat. Yet there is still massive whitespace ahead, since only a small portion of the world's diabetics use CGM technology despite its advantages. Abbott's work in this niche should provide a powerful long-term tailwind, but there will be many others. The company boasts other growth drivers, including its structural heart segment, where it markets a range of successful devices, such as its MitraClip device, a leader in its mitral valve repair niche. Beyond any single product, Abbott Laboratories has a proven track record as an innovator and should continue launching newer and better ones. Lastly, Abbott is also a Dividend King, and over the past decade, it has increased its payouts by almost 146%. Abbott Laboratories' business is built to last. Investors who purchase the company's shares today can expect consistent dividend growth over the long term. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025
CBC
4 hours ago
- CBC
Elon Musk announces new 'America Party' after Trump's massive spending bill becomes law
The dispute between U.S. Republican President Donald Trump and his main campaign financier Elon Musk took another fractious turn on Saturday when the space and automotive billionaire announced the formation of a new political party, saying Trump's "big, beautiful" tax bill would bankrupt America. A day after asking his followers on his X platform whether a new U.S. political party should be created, Musk declared in a post on Saturday: "Today, the America Party is formed to give you back your freedom." "By a factor of 2 to 1, you want a new political party and you shall have it!" he wrote. The announcement from Musk comes after Trump signed his self-styled "big, beautiful" tax-cut and spending bill into law on Friday, which Musk fiercely opposed. WATCH | What drove a wedge between Trump and Musk: Will Donald Trump and Elon Musk destroy each other? 25 days ago Duration 25:36 Musk, who became the word's richest man thanks to his Tesla car company and his SpaceX satellite firm, spent hundreds of millions on Trump's re-election and led the Department of Government Efficiency, aimed at slashing government spending, from the start of the president's second term. The first sign of investor dissatisfaction with Musk's announcement followed later in the day. Investment firm Azoria Partners will postpone the listing of a Tesla exchange-traded fund, Azoria CEO James Fishback said in a post on X. Fishback is asking Tesla's board to clarify Musk's political ambitions and said the new party undermines the confidence shareholders had that he would be focusing more on the company after leaving government service in May. Musk said previously that he would start a new political party and spend money to unseat lawmakers who supported the bill. Trump earlier this week threatened to cut off the billions of dollars in subsidies that Musk's companies receive from the federal government. Republicans have expressed concern that Musk's on-again, off-again feud with Trump could hurt their chances to protect their majority in the 2026 midterm congressional elections. Asked on X what was the one thing that made him go from loving Trump to attacking him, Musk said: "Increasing the deficit from an already insane $2T under Biden to $2.5T. This will bankrupt the country." There was no immediate comment from Trump or the White House on Musk's announcement. The feud with Trump, often described as one between the world's richest man and the world's most powerful, has led to several precipitous falls in Tesla's share price. The stock soared after Trump's November re-election and hit a high of more than $488 US in December, before losing more than half of its value in April and closing out last week at $315.35 US. Despite Musk's deep pockets, breaking the Republican-Democratic duopoly will be a tall order, given that it has dominated American political life for more than 160 years, while Trump's approval ratings in polls in his second term have generally held firm above 40 per cent, despite often divisive policies.
CTV News
4 hours ago
- CTV News
Trump's ‘reciprocal' tariff pause is about to expire. Cue the confusion
The 90-day deadline U.S. President Donald Trump set for countries to make trade deals with the United States or risk substantially higher tariffs is just days away. What will happen after that's reached at 12:01 a.m. ET on July 9 is anyone's best guess. The stakes could not be higher, with the entire global economy on notice. On April 2, a date Trump dubbed 'Liberation Day,' he unveiled new, 'reciprocal' tariff rates for key US trading partners, with some levies as high as 50 per cent. Collectively, the rates were the highest the US has charged on foreign goods in over a century. Economists quickly sounded alarms about a recession hitting not just certain countries, but rather the whole world. As the tariffs went into effect on April 9, they sparked a sell-off on Wall Street and the bond market rebelled, forcing Trump to announce a three-month pause to give countries more time to solidify deals with the US, saying investors 'were getting a little bit yippy, a little afraid.' Since then, almost all goods the US imports have been subject to a minimum 10 per cent tariff. Stocks, meanwhile, have not only recovered all those losses but have set multiple new record highs. And inflation has barely budged. But if tariffs start to rise again and inflation roars back, those gains could quickly get erased all over again. After months of meeting with foreign government officials and countless claims that several trading partners were on the cusp of completing deals, only three have been announced. One of those, with Vietnam, has yet to be finalized and few details are known about it. Still, the Trump administration is advertising that a flurry of deals are forthcoming. At the same time, the president has threatened to send letters to countries that don't ink deals, telling them the rate at which their exports to the US will be taxed. Leading up to July 9, Trump administration officials threatened to simply return to April tariff rates, or possibly even higher levies. They also floated the possibility of extending the pause for countries 'negotiating in good faith,' without defining what that means or which it includes. It's not clear where Trump, who will get the ultimate say, stands. 'We can do whatever we want. We could extend it; we could make it shorter,' Trump recently said. 'I'd like to make it shorter. I'd like to just sent letters out to everybody, 'Congratulations, you're paying 25 per cent.'' 'We'll look at how a country treats us — are they good, are they not so good — some countries we don't care, we'll just send a high number out,' Trump also recently said. On Friday, he said he'd begin sending letters over the coming days. 'They'll range in value from maybe 60 per cent or 70 per cent tariffs to 10 per cent and 20 per cent tariffs,' Trump said. For many countries, such rates would deal an even bigger economic blow compared to the levels Trump announced in April. But countries may have the opportunity to still negotiate, given Trump said most new rates won't take effect until August 1. America's evolving pain tolerance for higher tariffs The deal Trump announced on Wednesday with Vietnam, which calls for minimum tariffs of 20 per cent on Vietnamese goods, double the rate throughout the three-month pause, has raised the possibility that countries may not be able to score lower rates even if they reach a trade agreement. But considering tariffs on Vietnam were set to rise to a minimum of 46 per cent if the rates Trump announced in April held — which was among the highest Trump announced — 20 per cent suddenly feels like a relief. That may be an intentional strategy on Trump's part, allowing him to stick to his major campaign promise of levying higher tariffs on other nations in an effort to raise revenues and bring manufacturing jobs back to the US. 'On balance, we take the U.S.-Vietnam accord as a positive step toward more durable bilateral deals for the US and toward greater clarity for investors,' Ulrike Hoffmann-Burchardi, global head of equities at UBS Global Wealth Management, said in a note last week. 'Headline risks around trade may persist as negotiations continue, but we think the market impact should moderate as President Trump's negotiating tactics become increasingly familiar,' he said. 'Ultimately, we expect the US administration to prioritize economic stability over more maximalist tariffs, especially ahead of the 2026 midterm elections.' Elisabeth Buchwald, CNN
